The cell and gene therapy (CGT) landscape is evolving rapidly as drug developers seek new ways to deliver life-changing treatments to patients. While lentiviral (LV) and adeno-associated viral (AAV) vectors have historically dominated the spotlight, gammaretroviral vectors (RVVs) are driving a significant new wave of innovation. With a proven track record in approved chimeric antigen receptor (CAR) T-cell therapies and growing potential in next-generation ex vivo applications, RVVs are regaining ground.
However, the path from a promising preclinical RVV program to commercial reality is filled with complex manufacturing hurdles. For small to midsize biotechs and strategic pharma partners alike, mastering large-scale Good Manufacturing Practice (GMP) production requires moving beyond the lab bench to overcome specific technical and logistical difficulties.
Understanding these challenges is the first step toward building a scalable, reproducible and regulatory-ready program. Here, we explore the primary obstacles holding back retroviral programs and the innovations helping to clear the path to the clinic.
1. Limitations of traditional adherent scaling
Many RVV production processes still rely on traditional adherent manufacturing methods, such as roller bottles or Corning CellSTACKs® and HYPERStacks®. These systems have limited capacity and often force a “scale-out” strategy, increasing the number of units, rather than a true “scale-up” of a single unit’s capacity. This approach requires a larger facility footprint and increases the inherent risks of variability and contamination.
As well as helping to produce cleaner harvests, fixed-bed bioreactors can support higher cell densities and more consistent culture conditions within a closed, monitored system. Additionally, the development of suspension-based packaging lines is opening new possibilities for straightforward scale-up and higher yields as demand increases.
2. Vector fragility and shear stress
RVVs are enveloped and fragile, making them highly sensitive to physical and chemical stress. This sensitivity limits the feasibility of utilizing strong downstream purification steps, particularly certain chromatography methods. Consequently, many developers rely on minimal purification processes like basic tangential flow filtration (TFF). This approach may not provide the purity needed for advanced clinical stages without careful optimization.
Employing low-shear environments, such as those found in fixed-bed systems, protects RVV particles from the mechanical forces seen in large suspension reactors. Moving toward serum-free processes also creates more controlled conditions that improve consistency and support smoother downstream purification by reducing serum-related impurities.
3. The experience shortfall
A significant barrier to advancing RVV programs is the limited shared knowledge base. Much of the commercial RVV production expertise (e.g., in approved CAR-T therapies) remains internalized within large pharmaceutical companies. This trend has prevented the broader contract development and manufacturing organization (CDMO) community from building the deep, practical experience necessary to develop and optimize scalable RVV processes.
Partnering with a specialist CDMO provides access to experts with extensive and dedicated RVV experience. By leveraging a partner with established technical platforms, analytical strength and FDA-licensed facilities, RVV developers can advance their programs with confidence.
4. Meeting intensive analytical demands
As RVV programs move toward commercialization, analytical assays must be refined to define critical quality attributes (CQAs) for regulatory acceptance. Many developers struggle with the transition from research-grade assays to the robust, qualified methods required for GMP release.
Integrating analytical development early in the process establishes comparability as programs mature. Utilizing pre-qualified platform assays for core testing — combined with custom methods like vector copy number analysis — ensures safety, purity and potency while reducing the risks linked to late-stage method transfer.
The future of retroviral innovation
The next generation of CGTs will be defined by the ability to produce high-quality vectors with precision and speed. As the field moves toward more complex ex vivo applications, the demand for scalable, cost-conscious solutions will only grow.
By relying on a CDMO partner with deep RVV specialization and integrated manufacturing capabilities, developers can navigate the complexities of this evolving field while maintaining control over quality and timelines. Expert partners provide the scalable platforms and analytical depth necessary to protect vector integrity from early evaluation through commercial supply.
Ready to master your RVV manufacturing strategy?
Download our eBook, “Retroviral vectors: Shaping the next wave of cell and gene therapy innovation,” to explore how Genezen’s expertise and innovative platforms can help your program reach its full potential.
